EMEA-001741-PIP10-23 - paediatric investigation plan
upadacitinib
PIPHuman
Key facts
- Invented name
- Rinvoq
- Active Substance
- upadacitinib
- Therapeutic area
- Skin and subcutaneous tissue disorders
- Decision number
- P/0062/2024
- PIP number
- EMEA-001741-PIP10-23
- Pharmaceutical form(s)
- Prolonged-release tablet
- Age-appropriate oral liquid dosage form
- Condition(s) / indication(s)
- Treatment of alopecia areata
- Route(s) of administration
- Oral use
- Contact for public enquiries
Abbvie Limited
Email: paediatricteam@abbvie.com
Tel. +44 (0)1628 408248- Decision type
- P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
- Decision date